Therapeutic strategies for neuroendocrine liver metastases

Cancer

Volumn 121, Issue 8, 2015, Pages 1172-1186

  Frilling, Andrea ^a   Clift, Ashley K ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

liver; metastases; neuroendocrine tumors; treatment

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOXORUBICIN; EDOTREOTIDE LU 177; EDOTREOTIDE Y 90; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; LUTETIUM TETRAXETAN OCTREOTATE LU 177; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TETRAXETAN; TRACER; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG SAFETY; ECHOGRAPHY; HUMAN; IMMUNOMODULATION; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RADIOISOTOPE THERAPY; REVIEW; TUMOR ABLATION; TUMOR VASCULARIZATION; CLINICAL TRIAL (TOPIC); LIVER NEOPLASMS; NEUROENDOCRINE TUMORS; PERSONALIZED MEDICINE; SECONDARY; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HUMANS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; NEUROENDOCRINE TUMORS; TREATMENT OUTCOME;

EID: 84927018186     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28760     Document Type: Review

References (140)

1. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM,. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011; 40: 1-18, vii.
2. Ellis L, Shale MJ, Coleman MP,. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010; 105: 2563-2569.
3. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26: 3063-3072.
4. Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012; 95: 157-176.
5. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005; 12: 1083-1092.
6. Pape UF, Berndt U, Muller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008; 15: 1083-1097.
7. Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009; 16: 885-894.
8. Modlin IM, Lye KD, Kidd M,. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003; 97: 934-959.
9. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997; 8: 685-690.
10. Soga J,. Statistical evaluation of 2001 carcinoid cases with metastases, collected from literature: a comparative study between ordinary carcinoids and atypical varieties. J Exp Clin Cancer Res. 1998; 17: 3-12.
11. Norton JA, Jensen RT,. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004; 240: 757-773.
12. Saxena A, Chua TC, Perera M, Chu F, Morris DL,. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol. 2012; 21: e131-e141.
13. Yang TX, Chua TC, Morris DL,. Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases-a systematic review. Surg Oncol. 2012; 21: 299-308.
14. Valle JW, Eatock M, Clueit B, Gabriel Z, Ferdinand R, Mitchell S,. A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours. Cancer Treat Rev. 2014; 40: 376-389.
15. Gulenchyn KY, Yao X, Asa SL, Singh S, Law C,. Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol (R Coll Radiol). 2012; 24: 294-308.
16. Gurusamy KS, Pamecha V, Sharma D, Davidson BR,. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours [serial online]. Cochrane Database Syst Rev. 2009; 2: CD007118.
17. Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR,. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases [serial online]. Cochrane Database Syst Rev. 2009; 2: CD007060.
18. d'Assignies G, Fina P, Bruno O, et al. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging. Radiology. 2013; 268: 390-399.
19. Elias D, Lefevre JH, Duvillard P, et al. Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think. Ann Surg. 2010; 251: 307-310.
20. Klimstra DS,. Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging. Semin Oncol. 2013; 40: 23-36.
21. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE,. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009; 96: 175-184.
22. Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP,. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med. 2011; 41: 314-321.
23. Frilling A, Sotiropoulos GC, Radtke A, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010; 252: 850-856.
24. Ruf J, Heuck F, Schiefer J, et al. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology. 2010; 91: 101-109.
25. Jensen EH, Kvols L, McLoughlin JM, et al. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol. 2007; 14: 780-785.
26. Modlin IM, Drozdov I, Kidd M,. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood [serial online]. PLoS One. 2013; 8: e63364.
27. Cui T, Hurtig M, Elgue G, et al. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors [serial online]. PLoS One. 2010; 5: e16010.
28. Khan MS, Tsigani T, Rashid M, et al. Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clin Cancer Res. 2011; 17: 337-345.
29. Kinross JM, Drymousis P, Jimenez B, Frilling A,. Metabonomic profiling: a novel approach in neuroendocrine neoplasias. Surgery. 2013; 154: 1185-1192; discussion 1192-1183.
30. Saxena A, Chua TC, Sarkar A, et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery. 2011; 149: 209-220.
31. Scigliano S, Lebtahi R, Maire F, et al. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocr Relat Cancer. 2009; 16: 977-990.
32. Gomez D, Malik HZ, Al-Mukthar A, et al. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford). 2007; 9: 345-351.
33. Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003; 133: 375-382.
34. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG,. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003; 197: 29-37.
35. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT,. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003; 134: 1057-1063; discussion 1063-1055.
36. Nave H, Mossinger E, Feist H, Lang H, Raab H,. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery. 2001; 129: 170-175.
37. Coppa J, Pulvirenti A, Schiavo M, et al. Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplant Proc. 2001; 33: 1537-1539.
38. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001; 130: 677-682; discussion 682-675.
39. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000; 190: 432-445.
40. Pascher A, Steinmuller T, Radke C, et al. Primary and secondary hepatic manifestation of neuroendocrine tumors. Langenbecks Arch Surg. 2000; 385: 265-270.
41. Jaeck D, Oussoultzoglou E, Bachellier P, et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J Surg. 2001; 25: 689-692.
42. Kianmanesh R, Sauvanet A, Hentic O, et al. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg. 2008; 247: 659-665.
43. Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012; 255: 405-414.
44. Vouche M, Lewandowski RJ, Atassi R, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013; 59: 1029-1036.
45. Radtke A, Sotiropoulos GC, Molmenti EP, et al. Computer-assisted surgery planning for complex liver resections: when is it helpful? A single-center experience over an 8-year period. Ann Surg. 2010; 252: 876-883.
46. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010; 17: 3129-3136.
47. Mayo SC, de Jong MC, Bloomston M, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. 2011; 18: 3657-3665.
48. Mazzaferro V, Pulvirenti A, Coppa J,. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007; 47: 460-466.
49. Olausson M, Friman S, Herlenius G, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl. 2007; 13: 327-333.
50. Bonaccorsi-Riani E, Apestegui C, Jouret-Mourin A, et al. Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review. Transpl Int. 2010; 23: 668-678.
51. Frilling A, Malago M, Weber F, et al. Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transpl. 2006; 12: 1089-1096.
52. Florman S, Toure B, Kim L, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg. 2004; 8: 208-212.
53. Rosenau J, Bahr MJ, von Wasielewski R, et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation. 2002; 73: 386-394.
54. Marin C, Robles R, Fernandez JA, et al. Role of liver transplantation in the management of unresectable neuroendocrine liver metastases. Transplant Proc. 2007; 39: 2302-2303.
55. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl. 2006; 12: 448-456.
56. Cahlin C, Friman S, Ahlman H, et al. Liver transplantation for metastatic neuroendocrine tumor disease. Transplant Proc. 2003; 35: 809-810.
57. Le Treut YP, Gregoire E, Klempnauer J, et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013; 257: 807-815.
58. Nguyen NT, Harring TR, Goss JA, O'Mahony CA,. Neuroendocrine liver metastases and orthotopic liver transplantation: the US experience [serial online]. Int J Hepatol. 2011; 2011: 742890.
59. Gedaly R, Daily MF, Davenport D, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg. 2011; 146: 953-958.
60. Mangus RS, Tector AJ, Kubal CA, Fridell JA, Vianna RM,. Multivisceral transplantation: expanding indications and improving outcomes. J Gastrointest Surg. 2013; 17: 179-186; discussion 186-177.
61. Varkey J, Simren M, Bosaeus I, Krantz M, Gabel M, Herlenius G,. Survival of patients evaluated for intestinal and multivisceral transplantation-the Scandinavian experience. Scand J Gastroenterol. 2013; 48: 702-711.
62. Mazzaglia PJ, Berber E, Milas M, Siperstein AE,. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007; 142: 10-19.
63. Elias D, Goere D, Leroux G, et al. Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol. 2009; 35: 1092-1097.
64. Gillams A, Cassoni A, Conway G, Lees W,. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging. 2005; 30: 435-441.
65. Groeschl RT, Pilgrim CH, Hanna EM, et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg. 2014; 259: 1195-1200.
66. Vogl TJ, Naguib NN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NE,. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol. 2009; 72: 517-528.
67. Goering JD, Mahvi DM, Niederhuber JE, Chicks D, Rikkers LF,. Cryoablation and liver resection for noncolorectal liver metastases. Am J Surg. 2002; 183: 384-389.
68. Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E,. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery. 2010; 148: 1288-1293; discussion 1293.
69. Dong XD, Carr BI,. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol. 2011; 28 (suppl 1): S286-S290.
70. Vogl TJ, Gruber T, Naguib NN, Hammerstingl R, Nour-Eldin NE,. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. AJR Am J Roentgenol. 2009; 193: 941-947.
71. Christante D, Pommier S, Givi B, Pommier R,. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. Surgery. 2008; 144: 885-893; discussion 893-884.
72. Pitt SC, Knuth J, Keily JM, et al. Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg. 2008; 12: 1951-1960.
73. Schell SR, Camp ER, Caridi JG, Hawkins IF Jr., Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg. 2002; 6: 664-670.
74. Bhagat N, Reyes DK, Lin M, et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol. 2013; 36: 449-459.
75. Gaur SK, Friese JL, Sadow CA, et al. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol. 2011; 34: 566-572.
76. Whitney R, Valek V, Fages JF, et al. Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. Oncologist. 2011; 16: 594-601.
77. Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys. 2012; 83: 887-894.
78. Kalinowski M, Dressler M, Konig A, et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion. 2009; 79: 137-142.
79. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL,. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg. 2010; 251: 910-916.
80. Arrese D, McNally ME, Chokshi R, et al. Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma. Ann Surg Oncol. 2013; 20: 1114-1120.
81. Maire F, Lombard-Bohas C, O'Toole D, et al. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology. 2012; 96: 294-300.
82. Sward C, Johanson V, Nieveen van Dijkum E, et al. Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg. 2009; 96: 517-521.
83. Kamat PP, Gupta S, Ensor JE, et al. Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases. Cardiovasc Intervent Radiol. 2008; 31: 299-307.
84. Bloomston M, Al-Saif O, Klemanski D, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg. 2007; 11: 264-271.
85. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005; 104: 1590-1602.
86. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006; 13: 572-581.
87. Strosberg JR, Choi J, Cantor AB, Kvols LK,. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006; 13: 72-78.
88. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005; 241: 776-783; discussion 783-775.
89. Ozao-Choy J, Friedman ML, Kim AS, et al. Radioembolization for treatment of liver metastases from neuroendocrine tumors: correlation with imaging and biomarkers. Pancreas. 2013; 42: 358-360.
90. Benson AB 3rd, Geschwind JF, Mulcahy MF, et al. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer. 2013; 49: 3122-3130.
91. Paprottka PM, Hoffmann RT, Haug A, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol. 2012; 35: 334-342.
92. Shaheen M, Hassanain M, Aljiffry M, et al. Predictors of response to radio-embolization (TheraSphere) treatment of neuroendocrine liver metastasis. HPB (Oxford). 2012; 14: 60-66.
93. Lacin S, Oz I, Ozkan E, Kucuk O, Bilgic S,. Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response. Cancer Biother Radiopharm. 2011; 26: 631-637.
94. Cao CQ, Yan TD, Bester L, Liauw W, Morris DL,. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg. 2010; 97: 537-543.
95. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008; 31: 271-279.
96. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008; 247: 1029-1035.
97. Sofocleous CT, Petre EN, Gonen M, et al. Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases. J Vasc Interv Radiol. 2014; 25: 22-30; quiz 31.
98. Campana D, Capurso G, Partelli S, et al. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging. 2013; 40: 1197-1205.
99. Villard L, Romer A, Marincek N, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol. 2012; 30: 1100-1106.
100. Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011; 29: 2416-2423.
101. Bodei L, Cremonesi M, Grana CM, et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011; 38: 2125-2135.
102. Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010; 28: 1652-1659.
103. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26: 2124-2130.
104. Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006; 36: 147-156.
105. Frilling A, Weber F, Saner F, et al. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery. 2006; 140: 968-976; discussion 976-967.
106. Forrer F, Uusijarvi H, Storch D, Maecke HR, Mueller-Brand J,. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med. 2005; 46: 1310-1316.
107. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J,. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001; 12: 941-945.
108. van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ,. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2010; 51: 383-390.
109. Pach D, Sowa-Staszczak A, Kunikowska J, et al. Repeated cycles of peptide receptor radionuclide therapy (PRRT)-results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. Radiother Oncol. 2012; 102: 45-50.
110. Sabet A, Ezziddin K, Pape UF, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013; 54: 1857-1861.
111. van Vliet EI, de Herder WW, de Rijke YB, et al. Hypocalcaemia after treatment with [177Lu-DOTA 0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2013; 40: 1843-1852.
112. Horsch D, Ezziddin S, Haug A, et al. Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. Recent Results Cancer Res. 2013; 194: 457-465.
113. Kaemmerer D, Prasad V, Daffner W, et al. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol. 2009; 15: 5867-5870.
114. Sowa-Staszczak A, Pach D, Chrzan R, et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2011; 38: 1669-1674.
115. Stoeltzing O, Loss M, Huber E, et al. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg. 2010; 395: 185-192.
116. McStay MK, Maudgil D, Williams M, et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology. 2005; 237: 718-726.
117. Kratochwil C, Lopez-Benitez R, Mier W, et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer. 2011; 18: 595-602.
118. Claringbold PG, Brayshaw PA, Price RA, Turner JH,. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011; 38: 302-311.
119. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004; 15: 966-973.
120. Modlin IM, Pavel M, Kidd M, Gustafsson BI,. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010; 31: 169-188.
121. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000; 88: 770-776.
122. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27: 4656-4663.
123. Martin-Richard M, Massuti B, Pineda E, et al. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study [serial online]. BMC Cancer. 2013; 13: 427.
124. Eriksson B, Oberg K, Alm G, et al. Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet. 1986; 2: 1307-1309.
125. Oberg K,. The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol. 1992; 3: 35-41.
126. Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003; 21: 2689-2696.
127. Reidy-Lagunes D, Thornton R,. Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different? Curr Oncol Rep. 2012; 14: 249-256.
128. Moertel CG, Hanley JA, Johnson LA,. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980; 303: 1189-1194.
129. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004; 22: 4762-4771.
130. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006; 24: 401-406.
131. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K,. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011; 117: 4617-4622.
132. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C,. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol. 2003; 34: 18-27.
133. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008; 26: 1316-1323.
134. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 501-513.
135. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011; 331: 1199-1203.
136. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010; 28: 245-255.
137. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010; 28: 69-76.
138. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 514-523.
139. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011; 378: 2005-2012.
140. Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014; 15: e8-e21.